Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.49 million shsN/A
Penumbra, Inc. stock logo
PEN
Penumbra
$239.63
-0.3%
$248.21
$163.63
$310.00
$9.38B0.4536,873 shs551,771 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$35.50
+15.3%
$30.15
$23.69
$35.88
$13.49B0.681.14 million shs3.88 million shs
Solventum Corporation stock logo
SOLV
Solventum
$72.42
-1.1%
$74.21
$55.62
$85.92
$12.67B0.52595,556 shs869,954 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+73.21%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.45%+5.44%-4.35%-16.98%+34.96%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
+15.29%+12.40%+17.32%+25.20%+20.58%
Solventum Corporation stock logo
SOLV
Solventum
-1.12%-1.54%-7.03%+10.45%+29.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.3289 of 5 stars
1.10.00.00.00.02.50.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.8905 of 5 stars
4.54.00.03.73.12.51.9
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
3.1 of 5 stars
1.03.02.50.03.00.04.4
Solventum Corporation stock logo
SOLV
Solventum
1.3725 of 5 stars
2.14.00.00.03.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside
Penumbra, Inc. stock logo
PEN
Penumbra
2.94
Moderate Buy$300.4725.39% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$28.00-21.13% Downside
Solventum Corporation stock logo
SOLV
Solventum
2.27
Hold$84.3816.51% Upside

Current Analyst Ratings Breakdown

Latest NARI, SNN, SOLV, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$300.00 ➝ $310.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$330.00 ➝ $325.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$330.00 ➝ $335.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$315.00 ➝ $290.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$283.00 ➝ $285.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$340.00 ➝ $350.00
7/18/2025
Penumbra, Inc. stock logo
PEN
Penumbra
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/15/2025
Solventum Corporation stock logo
SOLV
Solventum
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$80.00 ➝ $103.00
7/9/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$320.00 ➝ $285.00
7/1/2025
Solventum Corporation stock logo
SOLV
Solventum
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$90.00
(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B7.82$2.88 per share83.28$33.18 per share7.22
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$5.81B2.68$3.64 per share9.75$12.04 per share2.95
Solventum Corporation stock logo
SOLV
Solventum
$8.25B1.52$9.83 per share7.37$17.13 per share4.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$3.7663.7347.832.1611.54%11.55%8.76%N/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$412M$2.1616.4417.750.94N/AN/AN/AN/A
Solventum Corporation stock logo
SOLV
Solventum
$478M$2.1633.5313.191.884.55%31.01%6.53%8/7/2025 (Estimated)

Latest NARI, SNN, SOLV, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Solventum Corporation stock logo
SOLV
Solventum
$1.45N/AN/AN/A$2.12 billionN/A
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81$0.86+$0.05$1.15$327.37 million$339.46 million
5/8/2025Q1 2025
Solventum Corporation stock logo
SOLV
Solventum
$1.19$1.34+$0.15$0.78$2.02 billion$2.07 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.892.51%N/A41.20%N/A
Solventum Corporation stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.75
4.04
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.89
1.33
Solventum Corporation stock logo
SOLV
Solventum
2.40
1.19
0.85

Institutional Ownership

CompanyInstitutional Ownership
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Solventum Corporation stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Solventum Corporation stock logo
SOLV
Solventum
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50039.00 million37.05 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
17,349437.98 million433.60 millionOptionable
Solventum Corporation stock logo
SOLV
Solventum
22,000173.01 million172.93 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inari Medical stock logo

Inari Medical NASDAQ:NARI

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Penumbra stock logo

Penumbra NYSE:PEN

$239.63 -0.76 (-0.32%)
Closing price 08/5/2025 03:59 PM Eastern
Extended Trading
$295.00 +55.37 (+23.11%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$35.50 +4.71 (+15.30%)
Closing price 08/5/2025 03:59 PM Eastern
Extended Trading
$35.55 +0.05 (+0.14%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$72.42 -0.80 (-1.09%)
Closing price 08/5/2025 03:59 PM Eastern
Extended Trading
$70.00 -2.42 (-3.34%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.